U.S. Markets open in 4 hrs 57 mins

New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)

First Study to Explore a Treat-to-Target Strategy in Crohn's Disease Using Endoscopy to Guide Dose Adjustment

First Study to Evaluate Intestinal Ultrasound Monitoring in an Interventional Setting

VIENNA, Feb. 14, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced interim data from the Phase 3b STARDUST study. At week 16, 79 percent of patients with moderately to severely active Crohn's disease (CD) achieved clinical response1 and 67 percent were in clinical remission2 after receiving one ~6 mg/kg intravenous (IV) dose followed by one 90 mg subcutaneous (SC) dose of STELARA® (ustekinumab), open label.3 Intestinal ultrasound (IUS) responses were assessed and were detected as early as week 4.4 Week 16 data (digital oral presentation, or DOP 13) and IUS response data (DOP 10) from STARDUST are being presented as digital oral presentations at the 15th Congress of the European Crohn's & Colitis Organization (ECCO).3,4

Janssen Pharmaceutical Companies of Johnson & Johnson logo (PRNewsfoto/Janssen Pharmaceutical Companie)

The primary endpoint of the 48-week STARDUST study is comparative endoscopic response5 among adult patients with CD receiving STELARA maintenance therapy. At week 16, patients who achieved a ≥70 point decrease in Crohn's Disease Activity Index score6 (CDAI70 responders) were randomized into treat-to-target or routine standard of care treatment groups at a 1:1 ratio.7

Of the 220 CDAI70 responders randomized to the treat-to-target arm, 37 percent achieved endoscopic response at week 16.3 Endoscopy at week 16 was measured only in the treat-to-target group.7 Treat-to-target is a proactive treatment strategy where frequently monitored outcomes, like endoscopic response, biomarkers and clinical symptoms, guide use of the medication.8 STARDUST is the first study of a treat-to-target strategy in CD using endoscopic response to guide treatment.

"Crohn's disease patients may respond to treatment while continuing to experience internal inflammation that can cause irreversible damage. These patients may benefit from a more proactive, robust treatment approach and less invasive monitoring methods," said Professor Silvio Danesei, Head of the Inflammatory Bowel Diseases Centre at Humanitas Research Hospital, Milan, Italy and principal investigator. "I am encouraged by these data, that demonstrate the potential clinical utility of the noninvasive IUS method in helping guide treatment of CD and look forward to forthcoming data that may help us better understand the possible benefits of a treat-to-target strategy."

IUS is a complementary method of assessing CD activity, based upon measuring transmural bowel features, like thickness of the bowel wall and presence of hypervascularization.9 STARDUST is the first study to use IUS for monitoring CD patients in an interventional setting. Future studies need to confirm whether early IUS response at week 4 is predictive of longer-term (i.e., week 16 and up to week 48) clinical and endoscopic outcomes for CD patients.

The STARDUST week 16 interim analysis includes 500 participants with moderately to severely active CD receiving an IV induction dose of STELARA ~6 mg/kg, followed by a STELARA 90 mg SC injection at week 8.3 In the interim analysis, patient response was assessed up to week 16. Participants were either naïve to prior biologics or had previously been exposed to no more than one biologic medicine. At week 16, the safety profile for STELARA in STARDUST was consistent with the established safety profile observed in Phase 3 inflammatory bowel disease (IBD) clinical trials, as well as that seen in other indications.10,11

"STARDUST represents a significant milestone in our commitment to helping Crohn's disease patients and the physicians who treat them," said Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader, Janssen Research & Development, LLC. "The data from this study may provide us with key clinical insights which may inform future treatment strategies."

Janssen is presenting a total of 23 abstracts at this year's ECCO congress. STELARA is currently approved for the treatment of adults with moderately to severely active Crohn's disease in the U.S., Canada, the European Union (EU) and Japan.

About the STARDUST Trial
STARDUST is a randomized, international, multi-center, interventional Phase 3b study evaluating the proportion of patients with endoscopic response, defined as a ≥50% reduction from baseline in simple endoscopic score for Crohn's disease (SES-CD) at week 48. STARDUST is evaluating 500 participants receiving an IV induction dose of STELARA 6 mg/kg, followed by a STELARA 90 mg SC injection at week 8. At week 16, patients with a CDAI reduction of ≥70 points (CDAI70) were randomized to treat-to-target or standard of care treatment arms (1:1 ratio) and will be followed through the end of the study (48 weeks). Primary endpoint data are anticipated for presentation later this year.

About Crohn's Disease (CD)
CD is one of the two main forms of IBD, which affect an estimated 3 million Americans.12 CD is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors. Symptoms of CD can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for CD.13

About STELARA® (ustekinumab)
STELARA® (ustekinumab), a human IL-12 and IL-23 antagonist, is approved in the United States for the treatment of: 1) adults and children 12 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; 2) adult patients (18 years or older) with active psoriatic arthritis, used alone or in combination with methotrexate (MTX); 3) adult patients (18 years and older) with moderately to severely active Crohn's disease; 4) adult patients (18 years and older) with moderately to severely active ulcerative colitis.

STELARA Dosing for Crohn's Disease
Adults with Crohn's disease will receive the first dose of STELARA through a vein in the arm (intravenous infusion) in a healthcare facility by a healthcare provider. It takes at least 1 hour to receive the full dose of medicine. STELARA will then be given as an injection under the skin (subcutaneous injection) 8 weeks after the first dose of STELARA, then every 8 weeks thereafter.

See full Prescribing Information for Dosing Information for other indications.

The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to STELARA®.

IMPORTANT SAFETY INFORMATION
STELARA® is a prescription medicine that affects your immune system. STELARA® can increase your chance of having serious side effects including:

Serious Infections
STELARA® may lower your ability to fight infections and may increase your risk of infections. While taking STELARA®, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.

  • Your doctor should check you for TB before starting STELARA® and watch you closely for signs and symptoms of TB during treatment with STELARA®.
  • If your doctor feels that you are at risk for TB, you may be treated for TB before and during treatment with STELARA®.

You should not start taking STELARA® if you have any kind of infection unless your doctor says it is okay.

Before starting STELARA®, tell your doctor if you:

  • think you have an infection or have symptoms of an infection such as:
  • are being treated for an infection.
  • get a lot of infections or have infections that keep coming back.
  • have TB, or have been in close contact with someone with TB.

After starting STELARA®, call your doctor right away if you have any symptoms of an infection (see above). STELARA® can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL‐12) and interleukin 23 (IL‐23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take STELARA® may also be more likely to get these infections.

Cancers
STELARA® may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving STELARA®. Tell your doctor if you have any new skin growths.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
RPLS is a rare condition that affects the brain and can cause death. The cause of RPLS is not known. If RPLS is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.

Serious Allergic Reactions
Serious allergic reactions can occur. Stop using STELARA® and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.

Lung Inflammation
Cases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn't go away during treatment with STELARA®.

Before receiving STELARA®, tell your doctor about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed above for serious infections, cancers, or RPLS.
  • ever had an allergic reaction to STELARA® or any of its ingredients. Ask your doctor if you are not sure.
  • are allergic to latex. The needle cover on the prefilled syringe contains latex.
  • have recently received or are scheduled to receive an immunization (vaccine). People who take STELARA® should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system, and can cause serious problems. You should not receive the BCG vaccine during the one year before receiving STELARA® or one year after you stop receiving STELARA®.
  • have any new or changing lesions within psoriasis areas or on normal skin.
  • are receiving or have received allergy shots, especially for serious allergic reactions.
  • receive or have received phototherapy for your psoriasis.
  • are pregnant or plan to become pregnant. It is not known if STELARA® can harm your unborn baby. You and your doctor should decide if you will receive STELARA®.
  • are breastfeeding or plan to breastfeed. It is thought that STELARA® passes into your breast milk. Talk to your doctor about the best way to feed your baby if you receive STELARA®.

Tell your doctor about all the medicines you take, including prescription and over‐the‐counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

When prescribed STELARA®:

  • Use STELARA® exactly as your doctor tells you to.
  • STELARA® is intended for use under the guidance and supervision of your doctor. In children 12 years and older, it is recommended that STELARA® be administered by a healthcare provider. If your doctor decides that you or a caregiver may give your injections of STELARA® at home, you should receive training on the right way to prepare and inject STELARA®. Your doctor will determine the right dose of STELARA® for you, the amount for each injection, and how often you should receive it. Do not try to inject STELARA® yourself until you or your caregiver have been shown how to inject STELARA® by your doctor or nurse.

Common side effects of STELARA® include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, stomach pain, diarrhea, and joint pain. These are not all of the possible side effects with STELARA®. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.

Please read the full Prescribing Information and Medication Guide for STELARA® and discuss any questions you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1800FDA1088.

cp-113880v1

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development and potential availability in the US of STELARA® (ustekinumab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, and any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1  Clinical response is defined as a decrease in Crohn's Disease Activity index (CDAI) score from baseline of ≥100 points, or a CDAI score of <150

2  Clinical remission is defined as a CDAI score of <150.

3  Danese, S., et. Al. Clinical and endoscopic response to ustekinumab in Crohn's Disease: Week 16 interim analysis of the STARDUST trial [Presentation for DOP13] Presented at the 15th Congress of the European Crohn's & Colitis Organization (ECCO) 12-15 February 2020; Vienna, Austria.

4  Kucharzik, T., et. Al. Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn's Disease: Week 16 interim analysis of the STARDUST trial substudy. [Presentation for DOP10] Presented at the 15th Congress of the European Crohn's & Colitis Organization (ECCO) 12-15 February 2020; Vienna, Austria.

5  Endoscopic response was defined by a 50 percent reduction from baseline in simple endoscopic score (SES-CD).

6  CDAI is a frequently used measure to assess the severity of CD, giving a score from 0–600; a higher score indicates more severe disease activity

7  ClinicalTrials.gov. Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab (STARDUST). Identifier NCT03107793. Available at: https://clinicaltrials.gov/ct2/show/NCT03107793. Accessed January 2020.

8  Smolen J, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task. Ann Rheum Dis 2015;0:1–13.

9  Fraquelli M et al. Impact of intestinal ultrasound on the management of patients with inflammatory bowel disease: how to apply scientific evidence to clinical practice. Dig Liver Dis 2020;52:9–18.

10  European Medicines Agency. STELARA Summary of product characteristics. 2020. Available at: https://www.medicines.org.uk/emc/product/7638/smpc. Accessed January 2020.

11  Sandborn WJ, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther 2018;48:65–77."

12  Overview of Crohn's Disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed January 2020.

13  Crohn's and Colitis UK. Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed January 2020.


i Professor Danese is a paid consultant for Janssen. He has not been compensated for any media work.

Media Contact:
Bridget Kimmel 
 (215) 688-6033 (mobile)

Investor Contacts:
Chris DelOrefice
(732) 524-2955 (office)

Lesley Fishman
(732) 524-3922 (office)

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-phase-3b-interim-data-from-stardust-study-show-two-thirds-of-patients-with-moderately-to-severely-active-crohns-disease-achieved-clinical-remission-after-two-doses-of-stelara-ustekinumab-301005006.html

SOURCE The Janssen Pharmaceutical Companies of Johnson & Johnson

  • Elon Musk Calls Bill Gates Underwhelming After Billionaire Buys a Porsche
    Business
    Bloomberg

    Elon Musk Calls Bill Gates Underwhelming After Billionaire Buys a Porsche

    If he was expecting kind words in return from Elon Musk, he apparently shouldn't have spoken about challenges that still lie ahead -- or about his new Porsche. Gates, the billionaire co-founder of Microsoft Corp., spoke with a YouTube influencer last week about the challenges of reducing emissions to slow climate change. “And certainly Tesla, if you had to name one company that's helped drive that, it's them,” Gates told YouTuber Marques Brownlee.

  • Wall Street Has a New Big Bull on Tesla
    Business
    Bloomberg

    Wall Street Has a New Big Bull on Tesla

    Piper raised its target to $928 from $729, making it the most bullish among forecasters tracked by Bloomberg. “It's easy to forget that TSLA sells batteries and solar power products; after all, the segment was only 6% of sales in 2019,” analysts Alexander Potter and Winnie Dong wrote in a Feb. 18 note. In order to gauge Tesla's chances of success in generating and storing solar power, the analysts recently installed a solar-based system to use for charging a Model X and the results have been “illuminating” so far, they wrote in the note.

  • Billionaire Ray Dalio Pulls the Trigger on 3 “Strong Buy” Stocks
    Business
    TipRanks

    Billionaire Ray Dalio Pulls the Trigger on 3 “Strong Buy” Stocks

    On top of this, he pointed out, “Debunking 'too big to grow fears,' BLK delivered 7%-plus organic asset growth for the full year 2019, which is an acceleration from 2.1%-plus organic growth in 2018 and 4.3%-plus average growth rate over last five years. Importantly, strong net new money growth translated into 5% organic base fee growth in 2019, better than the 2% growth in 2018. Based on this report, Cyprys expects other analysts to make adjustments to their outlooks for 2020.

  • Chinese Companies Say They Can’t Afford to Pay Workers Now
    Business
    Bloomberg

    Chinese Companies Say They Can’t Afford to Pay Workers Now

    With classes canceled at a coding-and-robotics school in Hangzhou, employees will lose 30% to 50% of their wages. The Lionsgate Entertainment World theme park in Zhuhai is closed, and workers have been told to use up their paid vacation time and get ready for unpaid leave.“A week of unpaid leave is very painful,” said Jason Lam, 32, who was furloughed from his job as a chef in a high-end restaurant in Hong Kong's Tsim Sha Tsui neighborhood. Across China, companies are telling workers that there's no money for them -- or that they shouldn't have to pay full salaries to quarantined employees who don't come to work.

  • 10 Stocks' Profit Will Soar More Than Anyone Dreamed, Analysts Say
    Business
    Investor's Business Daily

    10 Stocks' Profit Will Soar More Than Anyone Dreamed, Analysts Say

    Analysts' forecast for S&P 500 profit for 2020 has declined all year, says FactSet. Digging further shows you just how much. Analysts Souring On S&P 500 Earnings Most S&P 500 companies are expected to make less than thought in 2020, not more.

  • The Wuhan Virus and Research-Focused Biotech Companies
    Business
    GuruFocus.com

    The Wuhan Virus and Research-Focused Biotech Companies

    The problem with these companies is that their low or nonexistent revenues result in a weak investor perception as the qualitative benefits of their research cannot be measured tangibly. However, with the outbreak of the Wuhan coronavirus, the importance of investing in the research of such companies is suddenly a hot topic in the investor community, which is why many of these stocks have seen their prices rise. Warning!

  • InMode Reverses Lower
    Business
    Investor's Business Daily Video

    InMode Reverses Lower

    InMode reported strong earnings, sales and guidance … but after surging at the open shares reversed lower. Has a 53.30 cup-with-handle buy point. Looked like an early entry at the open – but good idea to wait 5 minutes or even for topping first-hour high, especially with a volatile IPO like INMD.

  • 3 “Strong Buy” Stocks Top Investors Are Snapping Up Right Now
    Business
    TipRanks

    3 “Strong Buy” Stocks Top Investors Are Snapping Up Right Now

    See Centene stock analysis on TipRanks) Applied Materials (AMAT) Next up is a fellow large cap, though from an entirely different sector. Semi-conductor company Applied Materials makes integrated circuit chips for a wide range of electronics, including TVs, smartphones and flat panel display screens. The $61 billion heavyweight's robust start to 2020 is a direct continuation of 2019's stellar performance; last year's gains of 90% have been boosted by a further 9% year-to-date.

  • Virgin Galactic's stock soars, fueled by retail investors
    Business
    Reuters

    Virgin Galactic's stock soars, fueled by retail investors

    Virgin Galactic Holdings Inc shares surged 24% on Tuesday, extending a rally since early December to over 400% and evoking a warning from an analyst who likes the space tourism company but warns it has become overbought. Shares of the company backed by billionaire Richard Branson have taken off in popularity among individual investors in recent sessions, nearly displacing Tesla Inc , another favorite among non-professional investors. Virgin Galactic was the third most traded stock on Fidelity's online brokerage in recent sessions, with two thirds of clients buying shares, rather than selling.

  • Dow Jones Futures: AMD Ignores Apple-Led Retreat; Enphase, SolarEdge, Amedisys, 10X Genomics, Palomar Are Key Movers
    Business
    Investor's Business Daily

    Dow Jones Futures: AMD Ignores Apple-Led Retreat; Enphase, SolarEdge, Amedisys, 10X Genomics, Palomar Are Key Movers

    Dow Jones futures rose modestly Tuesday, along with S&P 500 futures and Nasdaq futures. The stock market rally held up well Tuesday despite an Apple revenue warning on the coronavirus. Enphase Energy, Amedisys and 2019 IPO stocks 10X Genomics and Palomar Holdings reported earnings.

  • Business
    Barrons.com

    Tesla Stock Is Still Skyrocketing. Critics Are Giving Up.

    Investors who thought (TSLA) stock's volatility would calm down after its epic stock price rise are, apparently, wrong. Tesla (ticker: TSLA) stock was up more than 7% in trading on Tuesday, to about $858.40 a share at the close, after three bearish Wall Street analysts increased their price targets. None, however, upgraded the stock.

  • Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?
    Business
    Investor's Business Daily

    Marijuana Stocks Are Tumbling — Are Any Good Buys Right Now?

    Marijuana stocks received enormous hype after legal recreational sales took hold in Canada and sales became legal in some form or another across more than half of the U.S. Producers in Canada listed on the big U.S. exchanges, while their U.S. counterparts sought listings in Canada. Are any marijuana stocks on major U.S. exchanges a good buy now?

  • If you could buy only one stock for 5G and artificial intelligence exposure, this would be it
    Business
    MarketWatch

    If you could buy only one stock for 5G and artificial intelligence exposure, this would be it

    During the California gold rush, many miners went bankrupt. Most investors recognize that the gold rush is on in 5G and artificial intelligence. The picks and shovels for the present-day gold rushes are semiconductors.

  • Bloomberg's new plan to crack down on Wall Street includes a financial transaction tax
    Business
    Yahoo Finance

    Bloomberg's new plan to crack down on Wall Street includes a financial transaction tax

    Bloomberg has been campaigning as a more moderate alternative to candidates like Sen. Elizabeth Warren (D-MA) and Sen. Bernie Sanders (I-VT) and has been courting business leaders and Wall Street executives — who will likely cringe at the idea of a financial transaction tax. But the more progressive wing of the party has championed even tougher regulations and taxes on Wall Street on the wealthiest Americans. Bloomberg's financial transaction tax would be phased in gradually, starting at 0.02% to “monitor and minimize unintended consequences.

  • Walmart expects to save $60 million annually on shopping bags
    Business
    MarketWatch

    Walmart expects to save $60 million annually on shopping bags

    Walmart Inc. is saving big bucks on an unexpected part of the business: shopping bags. The world's largest company by revenue expects to save $60 million annually on plastic shopping bags, “just by changing our buying process and better utilizing our scale,” Chief Financial Officer Brett Biggs said. The remarks were made after the retail giant announced its fourth-quarter earnings on Tuesday.

  • Michael Burry's Scion Asset Management Buys 5 Stocks in the 4th Quarter
    Business
    GuruFocus.com

    Michael Burry's Scion Asset Management Buys 5 Stocks in the 4th Quarter

    GuruFocus has detected 5 Warning Signs with BBBY. Click here to check it out. BBBY 30-Year Financial Data The intrinsic value of BBBY Peter Lynch Chart of BBBY As of quarter-end, Scion's $82 million equity portfolio contains nine stocks, with turnover of 48%.

  • Here’s the reason Americans are saving so much of their income
    Business
    MarketWatch

    Here’s the reason Americans are saving so much of their income

    U.S. household wealth compared to income is near a record high. In the fourth quarter, savings as a percent of disposable income was 7.7%, more or less the post-crisis average. Some of the explanation can be boiled down to: Goldman's clients.

  • HSBC to slash 35,000 jobs as profit slumps
    Business
    Yahoo Finance Video

    HSBC to slash 35,000 jobs as profit slumps

    Shares of HSBC are under pressure as the largest European bank by assets announces it will cut 35,000 jobs and take $7.3 billion in charges as part of its overhaul. Yahoo Finance's Jared Blikre joins Seana Smith to discuss on The Ticker.

  • Roku, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates
    Business
    Simply Wall St.

    Roku, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates

    The yearly results for Roku, Inc. (NASDAQ:ROKU) were released last week, making it a good time to revisit its performance. Following the result, analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Following the latest results, Roku's 15 analysts are now forecasting revenues of US$1.61b in 2020.

  • Business
    TheStreet.com

    Nvidia Is at All-Time Highs, Yet It's Still Too Cheap

    For now, the stock remains cheaply valued and worth considering. Here's why: Faultless Fourth-Quarter Results Nvidia's fourth-quarter results were everything shareholders could have a wished for and more. Revenue was up 41% year over year, which drove gross profit margin expansions of more than 9%, and its adjusted per-share earnings numbers were up 136% year over year to $1.89.

  • What ‘Rothifying’ 401(k)s Would Mean for Retirees
    Business
    The Wall Street Journal

    What ‘Rothifying’ 401(k)s Would Mean for Retirees

    Research shows that switching 401(k)s to after-tax contributions would boost tax returns in the short term, but leave retirees worse off.

  • Business
    Barrons.com

    Alibaba Is a ‘Category Killer.’ Never Mind the Coronavirus, Analyst Says.

    dropped some bad, if not entirely surprising, news when it reported quarterly earnings on Feb. 13 and said that the coronavirus outbreak was having a negative impact on its business. The virus, Alibaba CEO Daniel Zhang said, was a “black swan event” that was having a negative impact on the company's employees and suppliers. CFO Maggie Wu said on a conference call, “While demand for goods and services is there, the means of production in the economy has been hampered by the delayed opening of offices, factories and schools after the Lunar New Year holiday.

  • Business
    GuruFocus.com

    SpaceX: Starlink IPO Should See Hope Trump Economics

    GuruFocus has detected 8 Warning Signs with IRDM. Click here to check it out. IRDM 30-Year Financial Data The intrinsic value of IRDM Peter Lynch Chart of IRDM An expensive endeavor Musk made Starlink the key pillar of his pitch to investors during SpaceX's most recent funding round, espousing his belief that it will be the profit engine that will drive the company's more ambitious, but less lucrative, pursuits.

  • Business
    TheStreet.com

    How Much Do Doctors Make?

    Doctors adhere to the Hippocratic Oath, which stems from Greek medical history, and calls for physicians to swear to uphold the highest ethical standards in the service of medicine. The numbers do vary for the average physician salary, depending on the source of the information. Data from ZipRecruiter notes the average annual pay for a "medical doctor" stands at $224,190 in 2018, with the highest salaries in the $397,000 range and on the lower end at $23,500.

  • Business
    Barrons.com

    12 Stock Picks That Will Please Both Growth and Value Investors

    As U.S. stocks continue to set record highs led by the fastest-growing companies, growth stocks have trounced value in recent years. With the bull market over a decade old and valuations toward the high end of their historical range, many have called for a comeback in value investing. Growth stocks are most simply defined as those that are expected to increase their earnings or revenues at a faster rate than the rest of the market.